There were 1,793 press releases posted in the last 24 hours and 358,385 in the last 365 days.

Contact

Please use this form to send email to PR contact of this press release:
Merck Announces FDA Accepts Samsung Bioepis’ Biologics License Application (BLA) for SB2 (Infliximab), an Investigational Biosimilar of Remicade

TO:



FROM:

Please check your email address!

Please, do not fill this field.

Please, do not change this field.

Please, do not fill if your javascript is turned off.

captcha image